KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Total Liabilities (2016 - 2026)

Pacira BioSciences has reported Total Liabilities over the past 17 years, most recently at $554.6 million for Q1 2026.

  • For Q1 2026, Total Liabilities fell 29.63% year-over-year to $554.6 million; the TTM value through Mar 2026 reached $554.6 million, down 29.63%, while the annual FY2025 figure was $571.8 million, 26.23% down from the prior year.
  • Total Liabilities for Q1 2026 was $554.6 million at Pacira BioSciences, down from $571.8 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $1.2 billion in Q1 2022 and troughed at $554.6 million in Q1 2026.
  • A 5-year average of $776.3 million and a median of $767.5 million in 2024 define the central range for Total Liabilities.
  • Biggest five-year swings in Total Liabilities: surged 85.62% in 2022 and later plummeted 36.09% in 2023.
  • Year by year, Total Liabilities stood at $906.2 million in 2022, then decreased by 22.28% to $704.3 million in 2023, then grew by 10.07% to $775.2 million in 2024, then decreased by 26.23% to $571.8 million in 2025, then fell by 3.0% to $554.6 million in 2026.
  • Business Quant data shows Total Liabilities for PCRX at $554.6 million in Q1 2026, $571.8 million in Q4 2025, and $570.4 million in Q3 2025.